RecruitingPhase 1Phase 2NCT07423546

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

A Multimodal PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

Sponsor

New York State Psychiatric Institute

Enrollment

12 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder

Summary

This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by \[18F\]DOPA Kicer (\[18F\]DOPA relative uptake rate)).

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Xanomeline and trospium chloride (KarXT) for people with schizophrenia 1 (disorder) and schizoaffecitve disorder. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXanomeline and trospium chloride (KarXT)

Subjects will be randomized to 5 weeks of low, middle, or high dose of Xanomeline and trospium chloride, and will complete a PET scan with \[18\]F DOPA at the beginning and end of the treatment period.